Gamma Light and Sound Stimulation for Alzheimer's Risk
This study is testing if a device called GENUS, which uses light and sound stimulation, can help prevent dementia in people at risk for Alzheimer's disease. Researchers believe that boosting gamma waves in the brain, which are important for memory, might reduce harmful protein deposits (amyloid and tau) linked to Alzheimer's. You might be able to join if you are 55-90 years old, have a close family member with Alzheimer's, and have normal memory. The study will measure changes in brain amyloid deposits over 12 months to see if the GENUS device is successful. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 200 participants, with 50 continuing in the main study. It is a blinded study, meaning neither you nor the researchers will know if you are receiving active or sham (inactive) stimulation.
- What's involved
- You would use the GENUS device at home for 60 minutes daily for 12 months. You would also have 4-6 visits to Massachusetts General Hospital for PET scans, MRI, EEG, blood tests, memory tests, and questionnaires.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your brain amyloid deposition will be measured at the start of the study and again at 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Diane Chan, MD PhD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Changes in brain amyloid deposition over the study period, as measured by PiB PET.Baseline to 12 months
The investigators will evaluate changes from baseline in amyloid deposition by using Pittsburgh compound B (PiB) PET, which is a standard for AD trial biomarkers, to assess progression towards AD with active or sham treatment.